Detalhe da pesquisa
1.
The genetic basis for cancer treatment decisions.
Cell
; 148(3): 409-20, 2012 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-22304912
2.
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
J Neurooncol
; 136(1): 79-86, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28988377
3.
Rare cancers: a sea of opportunity.
Lancet Oncol
; 17(2): e52-e61, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26868354
4.
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
Int J Cancer
; 132(7): 1547-55, 2013 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22948899
5.
Minding the gaps: assessing and addressing clinical research core competencies across a network of Canadian cancer centres.
Front Pharmacol
; 14: 1294335, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38143501
6.
Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
Cancer Cell
; 5(5): 411-5, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15144948
7.
The Impact of COVID-19 on Academic Cancer Clinical Trials in Canada and the Initial Response from Cancer Centers.
Curr Oncol
; 29(4): 2435-2441, 2022 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35448171
8.
Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
Future Oncol
; 7(7): 827-39, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21732754
9.
Advancing Academic Cancer Clinical Trials Recruitment in Canada.
Curr Oncol
; 28(4): 2830-2839, 2021 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34436014
10.
CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in Canada.
Curr Oncol
; 28(5): 3857-3865, 2021 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34677247
11.
Assessing benefit in trials: are we making progress in assessing progression in cancer clinical trials?
Cancer
; 121(11): 1728-30, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25336284
12.
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Support Care Cancer
; 18(4): 509-22, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20145956
13.
Use of predictive biomarkers in phase 2 trials.
Clin Adv Hematol Oncol
; 13(1): 23-5, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25679969
14.
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Lancet Oncol
; 10(3): 247-57, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19201650
15.
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.
Neurooncol Adv
; 2(1): vdaa124, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33235994
16.
Strategies for optimizing combinations of molecularly targeted anticancer agents.
Nat Rev Drug Discov
; 5(8): 649-59, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16883303
17.
Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Drugs
; 67(8): 1125-38, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17521215
18.
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
J Clin Oncol
; 23(25): 6172-80, 2005 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16135484
19.
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
J Clin Oncol
; 23(28): 7178-87, 2005 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16192602
20.
Therapeutic targets: MTOR and related pathways.
Cancer Biol Ther
; 5(9): 1065-73, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16969122